Alnylam Pharmaceuticals ^Investors

Alnylam Pharmaceuticals is a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2002 The company specializes in the development of innovative therapeutics based on RNA interference technology Alnylam has made significant investments in its research and development initiatives, with an investment scale of approximately $30 million The organization is committed to advancing the treatment of genetic diseases and has established a strong pipeline of product candidates With its focus on cutting-edge science, Alnylam continues to play a pivotal role in the biotechnology industry